Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression

Barbara J. McClure(South Australian Health and Medical Research Institute), Deborah L. White(ANZCHOG), Susan L. Heatley(ANZCHOG), Richard B. Lock(Cancer Institute of New South Wales), Teresa Sadras(South Australian Health and Medical Research Institute), Timothy P. Hughes(Royal Adelaide Hospital), Chung Hoow Kok(South Australian Health and Medical Research Institute), David T Yeung(Royal Adelaide Hospital), Rosemary Sutton(UNSW Sydney), Jiyuan An(Queensland University of Technology)
British Journal of Cancer
March 9, 2018
10.1038/s41416-018-0022-0
Cited by 44

Related Papers

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
|Nature|2012|1.6k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
|Blood|2013|705
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
|Leukemia|2012|440